Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy

P. Pane, R. Arcieri, M. Bonati, M. Bugarini, A. Didoni, E. Germinario

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The drugs prescribed to treat attention-deficit/hyperactivity disorder, one of the most prevalent psychiatric disease affecting children and adolescents, may risk causing harm. Recently, the U.S. Food and Drug Administration (FDA) has warned about liver and cardiovascular risks, and the European Medicines Agency (EMEA) had performed an assessment of risk-benefit ratio of psychostimulants. Pharmacovigilance in an Italian population aged 6-17 years suggests that atomoxetine is more likely to be reported as causing harm than methylphenidate.

Original languageEnglish
Pages (from-to)999-1002
Number of pages4
JournalAdverse Drug Reaction Bulletin
Issue number260
Publication statusPublished - Feb 2010

Fingerprint

Psychotropic Drugs
Attention Deficit Disorder with Hyperactivity
Italy
Pharmacovigilance
Safety
Methylphenidate
United States Food and Drug Administration
Psychiatry
Odds Ratio
Liver
Pharmaceutical Preparations
Population
Atomoxetine Hydrochloride

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pane, P., Arcieri, R., Bonati, M., Bugarini, M., Didoni, A., & Germinario, E. (2010). Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin, (260), 999-1002.

Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. / Pane, P.; Arcieri, R.; Bonati, M.; Bugarini, M.; Didoni, A.; Germinario, E.

In: Adverse Drug Reaction Bulletin, No. 260, 02.2010, p. 999-1002.

Research output: Contribution to journalArticle

Pane, P, Arcieri, R, Bonati, M, Bugarini, M, Didoni, A & Germinario, E 2010, 'Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy', Adverse Drug Reaction Bulletin, no. 260, pp. 999-1002.
Pane, P. ; Arcieri, R. ; Bonati, M. ; Bugarini, M. ; Didoni, A. ; Germinario, E. / Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. In: Adverse Drug Reaction Bulletin. 2010 ; No. 260. pp. 999-1002.
@article{d1d6fb3902054c6ca8ef418d1f14c5a4,
title = "Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy",
abstract = "The drugs prescribed to treat attention-deficit/hyperactivity disorder, one of the most prevalent psychiatric disease affecting children and adolescents, may risk causing harm. Recently, the U.S. Food and Drug Administration (FDA) has warned about liver and cardiovascular risks, and the European Medicines Agency (EMEA) had performed an assessment of risk-benefit ratio of psychostimulants. Pharmacovigilance in an Italian population aged 6-17 years suggests that atomoxetine is more likely to be reported as causing harm than methylphenidate.",
author = "P. Pane and R. Arcieri and M. Bonati and M. Bugarini and A. Didoni and E. Germinario",
year = "2010",
month = "2",
language = "English",
pages = "999--1002",
journal = "Adverse Drug Reaction Bulletin",
issn = "0044-6394",
publisher = "Lippincott Williams and Wilkins",
number = "260",

}

TY - JOUR

T1 - Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy

AU - Pane, P.

AU - Arcieri, R.

AU - Bonati, M.

AU - Bugarini, M.

AU - Didoni, A.

AU - Germinario, E.

PY - 2010/2

Y1 - 2010/2

N2 - The drugs prescribed to treat attention-deficit/hyperactivity disorder, one of the most prevalent psychiatric disease affecting children and adolescents, may risk causing harm. Recently, the U.S. Food and Drug Administration (FDA) has warned about liver and cardiovascular risks, and the European Medicines Agency (EMEA) had performed an assessment of risk-benefit ratio of psychostimulants. Pharmacovigilance in an Italian population aged 6-17 years suggests that atomoxetine is more likely to be reported as causing harm than methylphenidate.

AB - The drugs prescribed to treat attention-deficit/hyperactivity disorder, one of the most prevalent psychiatric disease affecting children and adolescents, may risk causing harm. Recently, the U.S. Food and Drug Administration (FDA) has warned about liver and cardiovascular risks, and the European Medicines Agency (EMEA) had performed an assessment of risk-benefit ratio of psychostimulants. Pharmacovigilance in an Italian population aged 6-17 years suggests that atomoxetine is more likely to be reported as causing harm than methylphenidate.

UR - http://www.scopus.com/inward/record.url?scp=77749245834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749245834&partnerID=8YFLogxK

M3 - Article

SP - 999

EP - 1002

JO - Adverse Drug Reaction Bulletin

JF - Adverse Drug Reaction Bulletin

SN - 0044-6394

IS - 260

ER -